The FDA has granted Priority Review to Johnson & Johnson's subcutaneous amivantamab for treating adults with recurrent or metastatic head and neck squamous cell carcinoma after progression on chemotherapy and immunotherapy. This drug uniquely targets EGFR and MET pathways, key drivers of tumor growth and resistance, showing a 42% overall response rate in trials, including complete responses in one-third of patients. If approved, it could offer a new treatment option for a cancer type with a poor five-year survival rate of 15%. The review shortens FDA evaluation to about six months, potentially speeding patient access to this innovative therapy.
In 2026, the ProShares Dividend Aristocrat ETF (NOBL) has outperformed the S&P 500 ETF (SPY), delivering a 12.9% return compared to SPY's 7.88%. Dividend Aristocrats, known for consistent dividend growth, averaged a 4.10% increase this year, with not...
Investors are rotating out of AI infrastructure stocks such as Micron and Western Digital, which surged earlier this year due to memory shortages but have recently declined. CNBC's Jim Cramer highlights a shift toward companies with broader growth dr...
Johnson & Johnson announced a $5.5 billion settlement to resolve about 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement covers federal and state claims but requires approval from 95% of claimants to finalize. ...
Johnson & Johnson has agreed to a $5.5 billion settlement to resolve about 76,000 lawsuits alleging its talc products caused ovarian cancer. The settlement aims to conclude a decade-long legal battle and requires participation from plaintiff firms re...
Johnson & Johnson has reached a historic $5.5 billion settlement to resolve claims from about 70,000 women and families alleging its talc products, including Johnson's Baby Powder, contained asbestos and caused cancers such as ovarian cancer and meso...
